Needham Reiterates Buy on Cytokinetics, Maintains $108 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintained a $108 price target on the stock.

April 09, 2024 | 9:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterated a Buy rating on Cytokinetics and maintained a $108 price target.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could lead to a positive short-term impact on Cytokinetics' stock price. The specific mention of a $108 price target suggests a significant upside potential from current levels, further underlining the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100